Ozempic, a medication used to treat type 2 diabetes and promote weight loss, is experiencing a surge in popularity within the pharmaceutical market. This is due to its effectiveness in managing blood sugar levels and its potential for weight loss. The increased use of Ozempic and other drugs in the GLP-1 drug class reflects a broader trend of consumers prioritizing their health and wellness.
As a result of this trend, various sectors within the US retail market are experiencing implications. Companies such as Hershey, Lululemon Athletica, Mondelēz International, NIKE, PepsiCo, and Walmart are mentioned in this report as having potential impacts on their businesses due to the widespread use of GLP-1 drugs.
This report is exclusive to subscribers only and provides valuable insights into the effects of widespread GLP-1 drug use on the retail industry. Subscribers can log in to access the document and gain important information on this topic. If you are not a subscriber but are interested in learning more about subscriptions and accessing relevant research, please visit our website for more information.